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Respiratory infection of BALB/c mice with the murine gammaherpesvirus 68 (MHV-68) induces the clonal
expansion of virus-specific cytotoxic T-lymphocyte (CTL) precursors (CTLp) in the regional, mediastinal
lymph nodes (MLN). Some of these CTLps differentiate to become fully functional CTL effectors, which can be
detected in both the lymphoid tissue and in the site of pathology in the lung. Though the lymph nodes and
spleen harbor substantial populations of latently infected B cells for life, the level of virus-specific CTL activity
decreases rapidly in all sites. The CD81 CTLp numbers fall to background levels in the MLN within several
months of the termination of the productive phase of MHV-68 infection in the respiratory epithelium but are
maintained at relatively low frequency in the spleen. The continued presence of a gamma interferon-producing,
MHV-68-specific CD41 set can also be demonstrated in cultured spleen cells. The virus-specific immunoglob-
ulin G (IgG) response is slow to develop, with serum neutralizing antibody and enzyme-linked immunosorbent
assay titers continuing to rise for several months. The level of total serum IgG increases dramatically within
2 weeks of infection, probably as a consequence of polyclonal B-cell activation, and remains high. The immune
response profile is clearly influenced by the persistence of this DNA virus.
Intranasal (i.n.) challenge with the murine gammaherpesvi-
rus 68 (MHV-68) leads to a transient, productive infection of
the respiratory epithelium, followed by life-long latency in B
lymphocytes (5, 27). The lytic phase in the lung recurs, with
ultimately lethal consequences, in mice that lack CD41 T cells
(5). This profile of acute replication in epithelia, followed by
persistence in other cell types and periodic (or late-onset)
reactivation, is typical for the herpesviruses (HVs). Indeed, the
interface between HV and host survival strategies through
phylogeny has led to the evolution of a variety of molecular
mechanisms designed to achieve a balance between immune
control and the need for virus excretion to ensure transmission
(3, 20, 29). The nature of the host response to these complex
viruses is thus of considerable, general interest.
The recently developed MHV-68 model clearly has consid-
erable potential for illuminating the long-term confrontation
between T cells, B cells, and the lymphotrophic gammaherpes-
viruses, which include Epstein-Barr virus (EBV), the Kaposi’s
sarcoma HV, and herpesvirus saimiri (6, 8, 12). Dissection of
the immune response to date has relied principally on the in
vivo depletion of T-cell subsets with monoclonal antibodies
(MAbs) and the use of various genetically disrupted (2/2)
mouse strains that lack particular components of the immune
system (5, 10, 31, 40). The principal themes so far are that both
the acute and persistent phases of MHV-68 infection seem to
be controlled by CD81 T cells, while CD41 T helper (Th)
activity is also required to achieve long-term protection. The
present analysis provides the first description of the MHV-68-
specific CD81 cytotoxic T-lymphocyte (CTL) response, to-
gether with kinetic studies of both immunoglobulin (Ig) pro-
files and the CD41 Th population.
MATERIALS AND METHODS
MHV-68 infection of the mice. The MHV-68 stocks were grown in owl monkey
kidney cells from an isolate originally provided by A. A. Nash (9). The female
BALB/cJ mice were purchased from Jackson Laboratory (Bar Harbor, Maine)
and, apart from the challenge with MHV-68, kept under specific-pathogen-free
conditions in the St. Jude Children’s Research Hospital Animal Resources Cen-
tre. Mice were anesthetized with Avertin (2,2,2-tribromoethanol) and infected
i.n. with 400 PFU of MHV-68 at 8 to 12 weeks of age (2, 5).
MHV-68-specific CTL assay. The virus-specific CTL assay for MHV-68 has
proven to be difficult to establish, and so the technique is described in some
detail. The BALB/c-3T3 cells (ATCC CCL163) were trypsinized, washed once,
and infected with MHV-68 at a multiplicity of infection of 10 for 1 to 2 h in
Dulbecco modified Eagle medium containing 10% fetal calf serum (FCS) (Hy-
Clone, Logan, Utah) at 37°C or left uninfected as controls. The cells were washed
once and labeled (0.2 mCi/106 cells) with 51Cr (Amersham Life Sciences, Ar-
lington Heights, Ill.) for 1 h at 37°C. After a further two washes, 5 3 103 targets
(per microculture) were incubated with the various lymphoid and inflammatory
cell populations in 96-well, flat-bottom plates (Sarstedt, Newton, N.C.) for 4 to
5 h before harvesting of supernatants for g counting. Threefold effector cell
dilutions from effector/target (E:T) ratios of 30:1 were measured in duplicate,
while the untreated and Triton X-100-disrupted (total release) controls were
assayed in quadruplicate. The percent specific lysis was calculated as 100 3 (51Cr
release from targets with effectors 2 51Cr release from targets alone)/(51Cr
release from targets with Triton 2 51Cr release from targets alone). The level of
51Cr release from MHV-68-infected targets alone was never .20% of the total
release.
Redirected CTL assay. A measure of the total level of CTL activity is provided
by the redirected assay, which utilizes a 4- to 6-h incubation with 51Cr-labeled
FcR1 Fas1 P815 target cells coated by a MAb to CD3e. The virus-specific CD81
CTLs will be included in this effector population, as will virus-specific CD41 T
cells and other activated CD3e1 lymphocytes that express the Fas ligand and/or
have up-regulated the perforin/granzyme mechanism (23, 28).
Restimulation in bulk culture. Spleen cells from naive mice were irradiated
and infected with MHV-68 at 0.1 PFU/cell for 1 h in RPMI 1640 supplemented
with penicillin (60 mg/ml), glutamine (2 mM), 10% FCS, and 30 mM 2-mercap-
toethanol (complete medium). These stimulator cells were washed once, irradi-
ated (2,000 rads), and incubated (0.5 3 106/ml) with responder lymphocytes
(1.5 3 106/ml) for 5 days in complete medium at 37°C with 5% CO2. Live cells
were purified from the cultures by centrifugation on a one-step Ficoll gradient
(Fisher Scientific, Pittsburgh, Pa.) and washed twice in complete medium before
use.
Limiting dilution analysis (LDA). The MHV-68-infected stimulators were
prepared as for bulk culture (see above), added (6 3 105/well) to twofold
dilutions of the responder cells in 96-well plates, and cultured in complete
medium for 7 days. Recombinant interleukin-2 (IL-2; 10 U/ml; Boehringer,
Indianapolis, Ind.) was provided on day 0 and again on day 5 of culture. After 7
days, 5,000 MHV-68-infected, 51Cr-labeled BALB/c-3T3 cells were added (per
microculture) to 20 replicate wells for each dilution of responder cells. Super-
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natants were harvested for gamma counting after 4 to 5 h. Positive wells were
taken as those with levels of specific 51Cr release .3 times the standard deviation
above the mean for 20 wells containing only the stimulator and target cell
populations. The prevalence of the CTL precursors (CTLp) was determined by
a regression plot of log10 (fraction of negative wells) against mean cell number,
with the correlation coefficient (r2) being greater than 0.9 in each case. The
values were corrected percent for the CD81 T cells determined by flow cyto-
metric analysis of the starting cell population and are expressed throughout as
CD81 CTLp frequencies.
Flow cytometry. Lymphocytes recovered directly from infected mice or from in
vitro bulk cultures were washed in phosphate-buffered saline (PBS), blocked by
incubation with 10% normal mouse serum, and stained (37) with anti-CD8a–
fluorescein isothiocyanate (FITC), anti-CD4-FITC, anti-CD62 ligand (CD62L)-
phycoerythin, and anti-B220-FITC (Pharmingen, San Diego, Calif.). The cells
were washed once after staining and analyzed on a FACScan, using Cellquest
software (Becton Dickinson, San Jose, Calif.).
Single-cell cytokine assay. The numbers of gamma interferon (IFN-g)-pro-
ducing cells in lymphocyte populations recovered from bulk cultures were de-
termined by the single-cell enzyme-linked immunosorbent assay (ELISA) spot
(ELISPOT) assay as described previously (33).
ELISA for virus-specific antibody. Virus was concentrated by ultracentrifuga-
tion from the supernatant of MHV-68-infected owl monkey kidney cells, dis-
rupted by dilution in PBS with 0.05% Triton X-100, and coated overnight at 4°C
onto Nunc Maxisorp immunoplates (Life Technologies, Gaithersburg, Md.). The
plates were washed five times with PBS-Tween (0.05%) and then incubated for
1 h at room temperature with PBS-Tween (0.05%)-bovine serum albumin (1%).
Fivefold serum dilutions from an initial concentration of 1/20 were incubated for
1 h, followed by a further five washes. Bound antibody was detected with alkaline
phosphatase (ALP)-conjugated rabbit anti-mouse IgG (Sigma Chemical Co., St.
Louis, Mo.), using n-nitrophenyl phosphate (Sigma) as the ALP substrate and
reading the absorbancy at 405 nm. Antibody titers were determined by compar-
ison with standard immune and naive sera included on each plate, with the
absorbancy of 1/20 naive mouse serum being characterized arbitrarily as 1 titer
unit.
ELISA for total IgG and IgM. Nunc Maxisorp plates were coated overnight at
4°C with either rabbit anti-mouse IgG (Sigma) or goat anti-mouse IgM (Sigma),
each 1 mg/ml in 50 mM NaHCO3 (pH 8.5), and then washed and blocked with
PBS-Tween-bovine serum albumin as above. A standard pool of mouse sera was
included on each plate for comparison. Fivefold serum dilutions started at
1/1,000 for IgM assays and 1/10,000 for IgG assays. Specific binding was detected
with ALP-rabbit anti-mouse IgG (Sigma) or ALP-goat anti-mouse IgM (Sigma).
All other steps were performed as described above.
Measuring neutralizing antibody. Duplicate twofold serum dilutions, starting
from an initial concentration of 1/10 in Dulbecco modified Eagle medium con-
taining 10% FCS, were incubated with 30 to 50 PFU of MHV-68 on ice for 1 h
in 96-well plates. Freshly trypsinized BALB/c-3T3 cells (2 3 104) were added to
each well and allowed to adhere overnight. The cells were then overlaid with
minimal essential medium containing 0.75% carboxymethyl cellulose. After 3 to
4 days of culture, the cells were fixed with methanol and stained with Giemsa
stain (Sigma). A standard immune serum was included in each experiment to
ensure uniformity of results. The neutralization titer was defined as the highest
serum dilution giving a greater than 50% reduction in viral plaques. Naive mouse
sera had no effect on plaque formation.
RESULTS
CTL effectors in the respiratory tract. Giving MHV-68 by
the i.n. route results in a primary phase of productive infection
in respiratory epithelium, which is generally resolved within 12
to 14 days. Mice that are depleted of the majority CD81 (but
not the CD41) T-cell subset fail to clear the virus and die (10).
Activated CD81 CD62Llo and CD41 CD62Llo T cells localize
to the infected lung, with peak cell counts being recorded for
the inflammatory exudate recovered (2) by bronchoalveolar
lavage (BAL) at about day 15 after the initial challenge (Fig.
1A). Previous experiments (5) have shown that both the CD41
and CD81 BAL populations contain CTLs that mediate CD3e-
dependent lysis of uninfected P815 target cells, an assay that
measures the total extent of T-cell activation rather than virus-
specific cytotoxicity.
Virus-specific CTL activity for H-2d-compatible, MHV-68-
infected major histocompatibility complex (MHC) class I1 II2
BALB/c 3T3 cells peaked in the BAL population at about 10
days after infection and remained at high levels for at least
another 10 days (Fig. 1B). The assay is virus specific, as the
targets were not lysed by BAL cells from MHV-68-infected
H-2b mice or from influenza virus-infected H-2d mice (Fig. 1B).
This profile of rapidly emerging CTL effector function coinci-
dent with virus clearance is also typical of respiratory infections
caused by the negative-strand RNA viruses (7), but the MHV-
68-specific T cells do seem to persist for somewhat longer in
the infected lung (Fig. 1A).
Lymphocyte numbers and CTLs in lymphoid tissue. Infec-
tion with MHV-68 causes a massive increase in counts for the
CD41 and CD81 T cells and B2201 B cells (Fig. 2) in the
spleen and regional, mediastinal lymph node (MLN) during
the acute phase of the disease process. The extent of passive
lymphocyte recruitment (38) may be reflected in the much
greater numbers of CD41 and CD81 T cells with a naive
CD62Lhi phenotype, while at least a proportion of the CD41
CD62Llo and CD81 CD62Llo sets (Fig. 2) will be comprised of
memory T cells specific for unrelated antigens (7). Others in
the activated CD62Llo populations will be lymphocytes that
have been stimulated in an MHV-68-specific or nonspecific
way, the latter being mediated either via a possible viral su-
perantigen or by cytokines (32, 35, 36).
Virus-specific CTL effectors can be detected in freshly iso-
lated MLN and spleen populations during the acute phase of
the infectious process (day 13; Fig. 3). The level of 51Cr release
for the MHV-68-infected targets was lower than that measured
by the antigen-nonspecific redirected protocol and was appar-
ent only at high E:T ratios. Little if any evidence of virus
FIG. 1. Recovery of antiviral CTL from the lung by BAL. Cells were pooled
from pairs of mice and adhered to plastic for 1 h at 37°C before assay to remove
macrophages. The proportion of activated T cells in each pool was determined
by flow cytometric analysis (A). CD81 CD62 Llo cells typically made up 40% of
the total at the peak of the response. Virus-specific cytotoxicity for an E:T ratio
of 30:1 (based on the total cells harvested) is shown in panel B. Net specific
lysis 5 % specific lysis of MHV-68-infected targets 2 % specific lysis of unin-
fected targets (which did not exceed 5%). Results were pooled from four sepa-
rate experiments. Each point shows the mean of one to three determinations. p,
MHV-68-specific cytotoxicity by BAL cells from influenza A/HKx31 virus-in-
fected BALB/c mice. , cytotoxicity for MHV-68-infected BALB/c-3T3 cells
mediated by BAL cells from MHV-68-infected C57BL/6 (H-2b) mice.
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replication is found in homogenates of MLN or spleen at any
phase of MHV-68 infection, though latent virus that can be
reactivated by culturing viable B cells in contact with suscep-
tible monolayers (infectious center assay) is present for life (4,
34). Perhaps the CTLs that can be assayed with the lytically
infected 3T3 targets (day 13; Fig. 3) are stimulated by antigen-
presenting dendritic cells that have localized from the respira-
tory tract (13, 25, 39). Constitutive MHV-68-specific CTL ac-
tivity was no longer apparent for MLN and spleen cells taken
at day 45 after infection, though some effector function was still
detectable by the redirected assay (day 45; Fig. 3).
Restimulation in bulk culture. Responding CD41 and
CD81 T cells dominated the lymphocyte populations recov-
ered after 5 days of in vitro culture for the first 30 or so days
after primary MHV-68 infection but tended to decrease in
relative prevalence at the later time points (Fig. 4A and B).
This drop in cell counts was particularly obvious for the CD81
set in the MLN (Fig. 4A). Somewhat surprisingly, many of
FIG. 2. Flow cytometric analysis of lymphocyte phenotypes before restimulation. Cells were pooled from two to three mice for each time point, and the mean
numbers of each cell type per mouse were derived from the total cell counts and the proportions stained specifically by flow cytometry. The results were pooled from
four separate experiments, with each point showing the mean of one to three determinations.
FIG. 3. Cytotoxic activity of lymphocyte population without prior restimula-
tion. Cells were pooled from three mice per time point and enriched for CD81
T cells by in vitro depletion with rat anti-mouse I-Ed and rat anti-mouse CD4
MAbs, followed by sheep anti-rat- and sheep anti-mouse-coated magnetic beads
(Dynal). The enriched populations contained 70 to 90% CD81 T cells and ,1%
CD41 T cells. The E:T ratios are corrected for to the number of CD81 T cells
in the effector cell populations. h, untreated BALB/c-3T3 cells; {, MHV-68-
infected BALB/c-3T3 cells; E, p815 cells plus anti-CD3 MAb.
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these cultured CD41 and CD81 T cells expressed the naive
CD62Lhi phenotype (Fig. 4A and B). Paralleling the cell
counts (Fig. 4A), the level of MHV-68-specific CTL activity
was maximal for the MLN populations taken within 30 days of
virus challenge but tended to decrease thereafter (Fig. 4C).
Both the drop in CD81 T-cell numbers with time and the
concurrent fall in CTL activity was less apparent for the spleen
(Fig. 4A and C).
Lymphocyte depletion experiments established that the vi-
rus-specific CTL effectors were indeed CD81 (Fig. 5), while
both the CD41 and CD81 T-cell subsets contributed to CD3e-
dependent cytotoxicity (CD4 or CD8 depleted; Fig. 5). The
numbers of functional CD41 T cells present after 5 days of in
vitro culture were measured independently by the single-cell
IFN-g ELISPOT assay (Fig. 4D). In general, the CD41 T-cell
counts for the MLN cultures did not vary (Fig. 4B) to the
FIG. 4. Functional analysis of MHV-68-specific T cells after restimulation in bulk culture. Cells were pooled from two to three mice and restimulated in vitro for
5 days with MHV-68-infected irradiated feeder cells (see Materials and Methods). (A and B) Percentages of activated (CD62Llo) and naive (CD62Lhi) T cells after
5 days of culture. The remainder of the cultured cells were almost all B2201 B lymphocytes. (C) Net percent specific lysis (% specific lysis of MHV-68-infected targets 2
% specific lysis of uninfected targets [which did not exceed 15%]) for an E:T ratio of 30:1 (lymph node cells) or 60:1 (spleen cells). E:T ratios refer to the total number
of live cells harvested from day 5 cultures. !, killing of MHV-68-infected H-2-mismatched NIH 3T3 cells. (D) IFN-g production by cells from the same restimulated
populations. This assay detects only responding CD41 T cells. {, CD8-depleted spleen cells; E, CD4-depleted spleen cells; v, restimulated naive spleen cells. Results
were pooled from four separate experiments, and each point shows the mean of one to three determinations.
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extent found for the CD81 subset (Fig. 4A), and IFN-g-pro-
ducing cells remained within a three- to fourfold range for
cultured spleen or MLN populations taken from 6 to 110 days
after infection (Fig. 4D).
Determining CTLp frequencies. Bulk CTL assays may es-
tablish that responding lymphocytes are indeed present in a
particular lymphoid organ (Fig. 4C and 5) but provide little
insight into the prevalence of the virus-specific T cells. Spleen
and MLN populations were thus stimulated for 7 days under
LDA conditions to determine CTLp frequencies (Table 1).
Typical regression lines are shown in Fig. 6. The results (Table
1; Fig. 6) are expressed relative to the percent CD81 T cells
determined by flow cytometric analysis of the spleen or MLN
population used to establish the LDA microcultures.
The virus-specific CTLp frequencies for MLN samples from
the acute phase of the response were reasonably high (1:200
CD81 T cells; Table 1), being roughly equivalent to 1:1,000
MLN lymphocytes. However, the CTLp numbers in the MLN
tended to decrease dramatically with time (day 67; Table 1).
The frequencies in the spleen were lower, but more consistent,
from days 10 to 134 after infection (Table 1). In general, the
time-related response profiles following bulk culture (Fig. 4C)
or LDA (Table 1) show some degree of correlation.
The antibody response. The level of total serum IgG in-
creased dramatically within 20 days of infection and remained
at a consistently high level thereafter (Fig. 7A). This was pre-
sumably a consequence of cytokine (or virus)-driven B-cell
activation (Fig. 2). CD41 T cells, which are necessary for the
virus-reduced splenomegaly (42), are also likely to have con-
tributed to this polyclonal B-cell response. The net effect may
be to diminish the effectiveness of virus-specific humoral im-
munity. The titers of MHV-68-specific antibody measured by
neutralization (Fig. 7B) or ELISA (Fig. 7C) were low during
the first 2 weeks or so after infection, though both tended to
increase progressively over the subsequent 50 to 70 days (Fig.
7B and C).
DISCUSSION
This is the first time that we have been able to demonstrate
MHV-68-specific CTL activity, though use of the redirected
assay with both conventional and perforin knockout (2/2)
H-2b-mice (16) indicated that potent CTL effectors mediating
target cell death via either the perforin/granzyme or the Fas/
Fas ligand pathway are generated during the course of this
infection (5). While perforin 2/2 H-2d mice were not available
for these experiments, it is likely from analysis with other
models of viral immunity that this MHV-68-specific CTL assay
measures only the perforin/granzyme component (16, 17).
Despite the fact that levels of specific 51Cr release as high as
75% were found in these experiments, it is by no means clear
that the present CTL assay is optimal. The HVs as a class have
developed a variety of mechanisms to minimize MHC class I1
peptide expression (11, 14, 18, 19, 22, 24). All that we know to
date about MHV-68 in this regard is that it does not seem to
cause any diminution in the level of MHC class I staining
(unpublished data). No peptide epitopes, or even source pro-
FIG. 5. CD8 dependence of virus-specific cytotoxicity. Spleen cells from mice
immunized i.n. 2 weeks earlier with MHV-68 were restimulated in vitro for 5
days. T-cell subsets were then depleted as indicated, using rat anti-mouse CD4 or
rat anti-mouse CD8 MAb followed by sheep anti-rat-coated magnetic beads. The
levels of virus-specific and redirected cytotoxicity were then determined as de-
scribed in Materials and Methods. h, uninfected BALB/c-3T3 cells; {, MHV-
68-infected BALB/c-3T3 cells; E, untreated p815 cells; , p815 cells plus anti-
CD3 MAb.
FIG. 6. Regression analysis of virus-specific CTLp frequencies. The plots are
typical of the LDA plots used to calculate the data in Table 1. The mean number
of CD81 T cells in the responder cell populations was calculated from the total
cell numbers and from flow cytometric staining.
TABLE 1. Generation and persistence of the
MHV-68-specific CD81 CTLp responsea
Day after
i.n. infection
Reciprocal CD81 CTLp
MLN Spleen
10 271 2,765
4,909
10 219 3,817
13 217 637
25 2,206 3,927
33 4,022
60 3,441
67 ,1/20,000 4,880
92 16,437
112 ,1/20,000 5,998
134 5,437
a Cells were pooled from three mice prior to restimulation in each case. The
frequencies determined by LDA, corrected for the percentage of CD81 T cells
in the starting population, are expressed as the reciprocal of the number of
MHV-68-specific CTLp per total CD81 T cells. Naive mice had ,1/20,000 CTLp
in the MLN and ,1/100,000 CTLp in the spleen.
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teins, have yet been identified for this virus, though the search
is in progress. Presumably the CTLs that we detect are specific
for lytic-phase proteins. The target cells produce infectious
virus and soon develop signs of cytopathology. However, it is
also possible that the measurable, redirected CTL activity
found in the lymphoid tissue in the long-term reflects the
presence of effectors specific for epitopes not expressed by the
infected 3T3 cells.
Given this reservation about the assay system, the acute
phase of the MHV-68-specific CD81 T-cell response seems to
be reasonably similar to that described for other virus infec-
tions. Effector CTLs are present in the inflammatory BAL
population recovered from the site of virus replication in the
lung, and substantial CTLp frequencies are found in the re-
gional MLN. Also, though evidence of productive infection is
not normally detected in homogenized lymphoid tissue, there
is some virus-specific CTL activity in the MLN and spleen. This
may indicate that virus-specific CTL eliminate any of the la-
tently infected B cells reverting to lytic phase.
The CTLp frequencies found for the MLN during the initial
stage of virus replication in the respiratory epithelium are
about equivalent to those recorded previously for the negative-
strand RNA viruses, such as Sendai virus and the influenza A
viruses. However, the progressive decrease in MHV-68-specific
MLN CTLp frequencies does not occur in mice that have
recovered from the transient infections caused by these RNA
viruses. Also, the CTLp numbers in the spleen are consistently
much lower for the MHV-68 model.
Perhaps continuing reactivation of MHV-68 from the large
pool of latently infected B cells leads to progressive immune
exhaustion (26). This does not, however, seem to be the case
for EBV (29), which has a somewhat similar pathogenesis.
Another possibility, in keeping with the high proportion of
activated T cells in the MLN at 10 to 25 days after infection
(Fig. 2), is that the MHV-68-specific memory CTLp population
is maintained in a state of partial activation that leads at least
some lymphocytes to undergo apoptosis after further stimula-
tion. Both potent CTL effectors and reasonable CTLp frequen-
cies could be demonstrated in lymphoid tissue before the
mononucleosis phase of virus-driven lymphocyte activation
(36). Further analysis of CTLp profiles may be more profitably
pursued when peptide-pulsed (rather than virus-infected) stim-
ulators can be used in the LDA protocol. A somewhat different
picture of the CD81 T-cell response in the long-term may well
emerge when assays are developed to measure CTLp frequen-
cies for epitopes expressed during the latent phase of the
infection.
Application of the IFN-g ELISPOT assay to lymphocyte
populations stimulated under bulk culture conditions indicated
that MHV-68-specific CD41 T-cell memory is also sustained in
the long term. Earlier studies with CD4-deficient MHC class II
2/2 H-2b-mice suggested that virus-specific CD41 Th is re-
quired to maintain effective CD81 T-cell-mediated control of
persistent MHV-68 infection. The lytic phase in the lung epi-
thelium reemerged in these MHC class II 2/2 mice, which
died from a progressive wasting disease after about 120 days
(5). The Th may also function to promote the production of
virus-specific IgG, which could act to limit the spread of the
reactivated virus (15).
Analysis of virus-specific Ig (ELISA) and neutralizing serum
antibody profiles indeed suggests that there is continuing,
MHV-68-specific Th in the lymphoid tissue, contributing to the
pattern of a low, delayed IgG class response that increases in
magnitude over several months. The fact that significant virus-
specific Ig levels are not detected until some 20 days after the
initiation of the infection may explain why only CD81 (and not
CD41) T-cell-mediated effector mechanisms are able to clear
MHV-68 from the respiratory tract (10). Perhaps the very
extensive B-cell activation (36, 41) that occurs during the first
month or more following the initial contact with MHV-68
subverts the specific humoral response. Similar B-cell activa-
tion has been described for EBV, but unlike the situation for
MHV-68, the increase is predominantly in serum IgM levels
(30). Naive B cells produce substantial amounts of IL-6 fol-
lowing in vitro infection with MHV-68 (32). Terminal B-cell
differentiation is known to be induced by IL-6 (1). It is also
possible that the virus-specific CD81 effectors eliminate B cells
that are both specific for MHV-68 and infected with the virus
(21), although any such effect cannot be absolute as there is a
progressive increase in neutralizing antibody titers.
This is the first kinetic analysis of immunity to a DNA virus
that is maintained as a latent infection in murine lymphoid
tissue. The analysis to date indicates that the continued pres-
FIG. 7. Kinetics of the virus-specific and total serum Ig response in mice
infected with MHV-68. Each point shows the mean and standard deviation of
results from three to six individual mouse sera pooled from four experiments.
The neutralizing antibody titer (B) was determined by plaque inhibition (see
Materials and Methods), whereas other antibody titers (A and C) were deter-
mined by ELISA. All measurements were made relative to a standard pool of
immune sera and are expressed in arbitrary units.
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ence of MHV-68 does not tend to increase the magnitude of
CD81 T-cell memory to peptides expressed during the acute
phase of the infectious process (7). The memory CD81 CTLp
pool specific for the readily eliminated negative-strand RNA
viruses is maintained at a much higher level. Perhaps the
MHV-68-specific CTLp population specific for these lytic epi-
topes is constantly being utilized to provide the effectors that
limit further virus production through the persistent phase of
the infection (5).
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